  |
Investment Highlights
Strong revenue growth
• 5 year CAGR growth of 21%
Healthy, robust business
• Generated 19.9 million of EBITDA in 2007 or $1.30 per share
Rich, near-term pipeline for growth
• 2 products awaiting regulatory approval
• 7 products in phase I, II and III
Financial data for ten years
|
(In thousands of Canadian dollars except for share and per share amounts) |
2007 |
2006 |
2005 |
2004 |
2003 |
2002 |
2001 |
2000 |
1999 |
1998 |
| Revenues |
62,941 |
48,357 |
33,923 |
28,017 |
23,859 |
23,355 |
17,795 |
12,607 |
11,201 |
6,023 |
|
Net Income (Loss) |
9,033 |
5,806 |
3,254 |
3,239 |
(4,172) |
5,162 |
1,485 |
2,797 |
2,016 |
836 |
|
Earnings (Loss) Per Share (Basic) |
0.60 |
0.39 |
0.22 |
0.22 |
(0.37) |
0.37 |
0.12 |
0.24 |
0.22 |
0.13 |
|
EBITDA |
19,913 |
15,420 |
9,371 |
7,633 |
4,564 |
8,377 |
5,040 |
2,905 |
2,873 |
2,555 |
|
Cash & marketable securities |
36,216 |
36,074 |
42,085 |
42,124 |
44,547 |
45,612 |
22,448 |
24,339 |
9,886 |
8,545 |
| Shareholders' Equity |
82,000 |
73,741 |
65,913 |
63,079 |
59,332 |
63,178 |
37,836 |
35,769 |
13,830 |
9,886 |
|
Shares issued and outstanding
|
14,902,784 |
14,980,131 |
14,732,368 |
14,858,469 |
14,799,588 |
14,780,205 |
12,539,247 |
12,394,038 |
9,466,338 |
9,057,731 |
|
|
